Abstract: Compounds of formula (I), wherein X is selected from the group consisting of O, and NR3, where R3 represents a lower alkyl group; Y is selected from the group consisting of CH and N; R1 and R2 are independently selected from the group consisting of NH2, NHR4 and NR52, where R4 and R5 each represent a lower alkyl group, or R1 and R2 together represent a cycle selected from (a), (b) and (c), wherein R6, R7 and R8 are independently selected from the group consisting of hydrogen atoms, lower alkyl groups, hydroxy groups and lower alkoxy groups; and Z is selected from the group consisting of O.

Abstract: Method for the treatment of endotoxic shock in mammals. The use of vasoactive intestinal peptide (VIP) and peptide activating hypofissiary adenylate cyclase (PACAP) is described in the treatment of endotoxic shock in mammals. These substances inhibit the production of tumor necrosis factor (TNF) and interleukin 6 (IL-6).

Abstract: The compositions for the preservation of organic tissues are comprised of a mixture from 12 to 70% of at least one dialkyl (C.sub.1 -C.sub.6)-keton peroxide, from 10 to 15% of glycerine, from 10 to 70% of at least one alcohol and, optionally, from 0 to 10% of a complementary marking, coloring and/or aromatic agent. Said compositions may be mixed with other appropriate agents or diluents, and can be applied especially to the preservation of tissues of all types, of human or origin, preferably by embalming or immersion.

Abstract: Said derivatives have the general formula (I) and are: ##STR1## (I-A) 4,6,7-trimethyl-5,8,8a,10a-tetrahydro-1H-1-azaanthracen-2,9,10-trione; (I-B) 2-ethoxy-3-methyl-1-azaanthracen-9,10-dione; (I-C) 3-ethyl-1,8-dihydro-1H-1,8-diazaanthracen-2,7,9,10-tetraone; (I-d) 2-acethoxy-3-methyl-1,8-diazaanthracen-2,9,10-trione; (I-e) 6-fluor-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-f) 6-dimethylamino-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-g) 4-methyl-5-(2-nitrophenyl)-5,8-dihydro-1H-1,8-diazaanthracen-2,9,10-trione ; (I-h) 3,5-dimethyl-1,8-dihydro-1,8-diazaanthracen-2,7,9,10-tetraone; (I-i) 3,6-difluor-1,8-diazaanthracen-9,10-dione; (I-j) 6-methyl-3-phenyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-k) 3-fluor-4-methyl-1-dihydro-1-azaanthracen-9,10-dione; 3-fluor-1-azaanthracen-1,10-dione. Application as antitumor agents.

Abstract: Azaanthracene-triones of the formula: ##STR1## (in which: R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are the same or are different and each is a hydrogen atom or a lower alkyl group;R.sup.3 is a hydrogen atom, a lower alkyl group, a phenyl group or an amino-substituted phenyl group; andX is a --CH--, .dbd.N-- or --NH--, whereby the ring containing the group X is a benzene, pyridine or dihydropyridene ring)have antitumoral activity.